Cargando…
Antidementia drug treatment in dementia networks in Germany: use rates and factors associated with treatment use
BACKGROUND: Dementia networks in Germany constitute a specialised setting for integrated dementia care and have shown benefits on relevant outcomes, including those of drug treatment. National guidelines recommend treatment with acetylcholinesterase inhibitors (donepezil, galantamine, rivastigmine)...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4460966/ https://www.ncbi.nlm.nih.gov/pubmed/25998147 http://dx.doi.org/10.1186/s12913-015-0855-7 |
_version_ | 1782375470267891712 |
---|---|
author | Wübbeler, Markus Wucherer, Diana Hertel, Johannes Michalowsky, Bernhard Heinrich, Steffen Meyer, Saskia Schaefer-Walkmann, Susanne Hoffmann, Wolfgang Thyrian, Jochen René |
author_facet | Wübbeler, Markus Wucherer, Diana Hertel, Johannes Michalowsky, Bernhard Heinrich, Steffen Meyer, Saskia Schaefer-Walkmann, Susanne Hoffmann, Wolfgang Thyrian, Jochen René |
author_sort | Wübbeler, Markus |
collection | PubMed |
description | BACKGROUND: Dementia networks in Germany constitute a specialised setting for integrated dementia care and have shown benefits on relevant outcomes, including those of drug treatment. National guidelines recommend treatment with acetylcholinesterase inhibitors (donepezil, galantamine, rivastigmine) or the N-Methyl-D-Aspartate antagonist (memantine) to reduce cognitive symptoms. However, prescription rates are lower than 30 % in general practises. This study aims to describe antidementia drug treatment and the factors that are associated with the treatment in different dementia networks across Germany. METHODS: We have analysed the socio-demographic, clinical and utilisation data from 560 patients with dementia (PWD), as well as data from their caregivers, in 13 selected dementia networks in Germany. The patients and caregivers were interviewed in their homes or in the network facilities. Multiple logistic regression models were fitted to evaluate the socio-demographic and clinical factors associated with the utilisation of antidementia drug treatment in the various networks. RESULTS: In all of the networks in the study, 52 % of the participants received an antidementia drug treatment. Factors associated with the utilisation of the antidementia drug treatment were: formal diagnosis (OR = 16.81, p < 0.001), association with a physician in the network (OR = 3.69, p < 0.001), higher number of comorbidities (OR = 0.88, p = 0.039), living alone (OR = 0.51, p = 0.032) and higher age (OR = 2.97, p = 0.002). CONCLUSION: Medical treatment of PWD with antidementia drugs in dementia networks in Germany is more frequent than in primary and nursing home care settings. Our findings also suggest that participants with a formal diagnosis and a physician in the network have increased rates of receiving antidementia drug treatments. These findings suggest that dementia networks focusing on medical treatment should support diagnostic procedures and incorporate physician specialists. |
format | Online Article Text |
id | pubmed-4460966 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-44609662015-06-10 Antidementia drug treatment in dementia networks in Germany: use rates and factors associated with treatment use Wübbeler, Markus Wucherer, Diana Hertel, Johannes Michalowsky, Bernhard Heinrich, Steffen Meyer, Saskia Schaefer-Walkmann, Susanne Hoffmann, Wolfgang Thyrian, Jochen René BMC Health Serv Res Research Article BACKGROUND: Dementia networks in Germany constitute a specialised setting for integrated dementia care and have shown benefits on relevant outcomes, including those of drug treatment. National guidelines recommend treatment with acetylcholinesterase inhibitors (donepezil, galantamine, rivastigmine) or the N-Methyl-D-Aspartate antagonist (memantine) to reduce cognitive symptoms. However, prescription rates are lower than 30 % in general practises. This study aims to describe antidementia drug treatment and the factors that are associated with the treatment in different dementia networks across Germany. METHODS: We have analysed the socio-demographic, clinical and utilisation data from 560 patients with dementia (PWD), as well as data from their caregivers, in 13 selected dementia networks in Germany. The patients and caregivers were interviewed in their homes or in the network facilities. Multiple logistic regression models were fitted to evaluate the socio-demographic and clinical factors associated with the utilisation of antidementia drug treatment in the various networks. RESULTS: In all of the networks in the study, 52 % of the participants received an antidementia drug treatment. Factors associated with the utilisation of the antidementia drug treatment were: formal diagnosis (OR = 16.81, p < 0.001), association with a physician in the network (OR = 3.69, p < 0.001), higher number of comorbidities (OR = 0.88, p = 0.039), living alone (OR = 0.51, p = 0.032) and higher age (OR = 2.97, p = 0.002). CONCLUSION: Medical treatment of PWD with antidementia drugs in dementia networks in Germany is more frequent than in primary and nursing home care settings. Our findings also suggest that participants with a formal diagnosis and a physician in the network have increased rates of receiving antidementia drug treatments. These findings suggest that dementia networks focusing on medical treatment should support diagnostic procedures and incorporate physician specialists. BioMed Central 2015-05-22 /pmc/articles/PMC4460966/ /pubmed/25998147 http://dx.doi.org/10.1186/s12913-015-0855-7 Text en © Wübbeler et al. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Wübbeler, Markus Wucherer, Diana Hertel, Johannes Michalowsky, Bernhard Heinrich, Steffen Meyer, Saskia Schaefer-Walkmann, Susanne Hoffmann, Wolfgang Thyrian, Jochen René Antidementia drug treatment in dementia networks in Germany: use rates and factors associated with treatment use |
title | Antidementia drug treatment in dementia networks in Germany: use rates and factors associated with treatment use |
title_full | Antidementia drug treatment in dementia networks in Germany: use rates and factors associated with treatment use |
title_fullStr | Antidementia drug treatment in dementia networks in Germany: use rates and factors associated with treatment use |
title_full_unstemmed | Antidementia drug treatment in dementia networks in Germany: use rates and factors associated with treatment use |
title_short | Antidementia drug treatment in dementia networks in Germany: use rates and factors associated with treatment use |
title_sort | antidementia drug treatment in dementia networks in germany: use rates and factors associated with treatment use |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4460966/ https://www.ncbi.nlm.nih.gov/pubmed/25998147 http://dx.doi.org/10.1186/s12913-015-0855-7 |
work_keys_str_mv | AT wubbelermarkus antidementiadrugtreatmentindementianetworksingermanyuseratesandfactorsassociatedwithtreatmentuse AT wuchererdiana antidementiadrugtreatmentindementianetworksingermanyuseratesandfactorsassociatedwithtreatmentuse AT herteljohannes antidementiadrugtreatmentindementianetworksingermanyuseratesandfactorsassociatedwithtreatmentuse AT michalowskybernhard antidementiadrugtreatmentindementianetworksingermanyuseratesandfactorsassociatedwithtreatmentuse AT heinrichsteffen antidementiadrugtreatmentindementianetworksingermanyuseratesandfactorsassociatedwithtreatmentuse AT meyersaskia antidementiadrugtreatmentindementianetworksingermanyuseratesandfactorsassociatedwithtreatmentuse AT schaeferwalkmannsusanne antidementiadrugtreatmentindementianetworksingermanyuseratesandfactorsassociatedwithtreatmentuse AT hoffmannwolfgang antidementiadrugtreatmentindementianetworksingermanyuseratesandfactorsassociatedwithtreatmentuse AT thyrianjochenrene antidementiadrugtreatmentindementianetworksingermanyuseratesandfactorsassociatedwithtreatmentuse |